Skip to content
DE

Anti-CCP reference ranges: what a positive or negative result means

Clinical review pending

How to interpret an anti-CCP result, why laboratory cutoffs differ, and what positive and negative tests mean when rheumatoid arthritis is suspected.

A hand holds an open blank book with three colored windows.

An anti-CCP result below 20 is considered negative in some assays, but the units and cutoff on your own laboratory report are what matter. Some tests report U, others U/mL, and an assay studied with a cutoff of 17 U/mL uses a different interpretation. A positive result can strongly support a diagnosis of rheumatoid arthritis when the symptoms fit. A negative result does not rule it out in someone with persistent joint symptoms.

What the anti-CCP test measures

Anti-CCP antibodies recognize cyclic citrullinated peptides. The test uses these peptides to detect a group of autoantibodies commonly found in rheumatoid arthritis, or RA. Citrullination itself is a normal process in which arginine within a protein is converted to citrulline. Citrullination does not always trigger an autoimmune response.

In some people, the immune system begins targeting citrullinated structures. Genetic susceptibility and environmental exposures may interact. A model of how these immune responses develop connects smoking, HLA-related genetic factors, and citrullinated autoantigens. A positive antibody result does not, however, establish that joint damage is already present.

Anti-CCP is relatively specific for RA. A meta-analysis of diagnostic accuracy estimated pooled sensitivity at 67% and specificity at 95%. High specificity means that people without the disease are relatively unlikely to test positive. It is not the same as the probability that an individual with a positive result has RA; that probability also depends on why the test was ordered and how likely RA was beforehand.

Results may be reported in U, U/mL, or EU/mL. Different assay generations, antigens, and instruments can produce different numerical results. A comparison of CCP3 and CCP3.1 assays found broadly similar diagnostic performance and strong agreement in the studied cohorts. Similar overall performance does not make every numerical result interchangeable between methods. Interpret a value with the reference range supplied by the laboratory that measured it.

Reference ranges and the idea of an “optimal” result

Anti-CCP is not a nutrient that needs to be optimized within a target range. A negative result is generally reassuring about these particular antibodies, but there is no additional universally accepted “optimal” value that guarantees healthy joints regardless of assay or symptoms.

A small proportion of people without known RA can test positive. The percentage depends on the population and assay. Frequently quoted figures such as 1–3% are not universal. In one study using stored blood donations, anti-CCP was present in 0.6% of control samples, not 1–3% of all healthy people. Samples and individuals are also different denominators. In some people antibodies precede later arthritis; others do not go on to develop it.

Low antibody levels are not always irrelevant. A two-year prospective study examined people who already had undifferentiated arthritis. Its findings cannot simply be applied to someone without symptoms whose result is just below a laboratory cutoff. “Low positive” and “negative but close to the cutoff” are not equivalent categories.

Small changes within the negative range are therefore not independent evidence that RA is beginning. Whether another test would help depends on symptoms, the examination, and the assay, rather than a desire to push the number lower.

What a positive result means

The following Mayo Clinic Laboratories interpretation is an example for a specific assay, not a universal standard. Mayo reports this test in U; do not transfer the thresholds to a different method simply because its numbers look similar.

Anti-CCP result in U for this assay Interpretation
Below 20.0 Negative
20.0–39.9 Weak positive
40.0–59.9 Positive
60.0 or above Strong positive

Other assays use different cutoffs. A study of the Elecsys assay evaluated 17 U/mL as a diagnostic cutoff in its studied population. That is not a universal boundary between healthy and unhealthy joints. In classification criteria, antibody levels are also considered relative to the upper limit of normal for the particular laboratory. The ACR/EULAR criteria combine antibody findings with joint involvement, inflammatory markers, and symptom duration. They are a framework for classifying disease, not a diagnosis generated by one blood result.

When joint symptoms fit, a positive anti-CCP result increases the likelihood of RA. Higher titers have been associated with a greater risk of developing RA or more severe joint outcomes in some studied groups. They do not determine what will happen to an individual.

Antibodies can be detectable years before symptoms, sometimes 5–10 years or longer. A study of antibodies before disease onset and the serial blood-donor study support that separation in time. In the latter, positivity for anti-CCP and/or IgM rheumatoid factor preceded symptoms by a median of 4.5 years among those positive before onset, with a range of 0.1–13.8 years. That combined-marker result is not an anti-CCP-only prediction. A positive result cannot establish either a precise onset date or a certain future diagnosis.

In established early RA, researchers have examined links with later joint damage, including a prognostic study and a study of radiographic damage after five years. Anti-CCP can therefore contribute to the overall assessment, but it does not replace an examination of current disease activity.

Positive results can also occur in other inflammatory or autoimmune conditions. Specificity is often quoted around 95–98%, but it varies with assay and the comparison population; the diagnostic meta-analysis above pooled it at 95%. A result should not be treated as a stand-alone diagnosis without the joint examination and medical history.

What a negative result means

A negative result means that the assay did not detect antibodies above its defined cutoff. It does not demonstrate the absence of all autoimmune activity. There is no medically concerning “too low” anti-CCP level.

Some people with RA are seronegative, meaning that both anti-CCP and rheumatoid factor are negative. Estimates such as 20–30% depend on the population and definition and should not be treated as a fixed proportion in every clinic. A cohort study of seronegative early inflammatory arthritis illustrates why these cases still require clinical attention.

Persistent joint swelling, prolonged morning stiffness, or a pattern of similar symptoms on both sides of the body deserves assessment even with a negative anti-CCP result. For someone without symptoms, a negative result also cannot predict every future immune change. It provides information at the time of testing, rather than a lifelong guarantee.

What happens during testing?

The test uses blood drawn from a vein. Fasting or a special diet is generally unnecessary for anti-CCP alone. Do not stop medicines on your own. If other tests are being done at the same time, their preparation requirements may differ.

Many assays are immunoassays, including ELISA methods. Results may be available within 1–3 business days, but turnaround time varies by laboratory. If results are being compared over time, using the same method makes interpretation easier.

Repeating testing every 2–3 years because of risk factors, or every 6–12 months for a near-cutoff result, is not a general rule. A repeat test should answer a specific clinical question. New joint swelling calls for timely clinical assessment, not waiting for an arbitrary testing interval.

Rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) are often considered alongside anti-CCP. Genetic tests, including HLA-DRB1-related testing, address more specialized questions and are not a necessary part of every evaluation.

What can influence anti-CCP and the risk of RA?

Once present, anti-CCP antibodies often remain relatively stable. They are not a direct measure of every short-term change in inflammation, pain, or stress. Repeated antibody measurements do not replace assessment of the joints, and treatment should not be changed solely because the titer moves.

Smoking is a well-studied risk factor, particularly alongside genetic susceptibility. A meta-analysis of smoking and RA and the HLA and citrullination model examine this relationship. Stopping smoking is worthwhile without waiting to see what happens to anti-CCP.

Mucosal tissues, infection, and oral health are also being investigated as possible contributors to disease development. A study of periodontitis and Porphyromonas gingivalis examines related associations. Good dental care matters, but these findings do not establish that it specifically lowers anti-CCP or prevents RA.

Pregnancy and the period after delivery can affect disease activity. A review of immune adaptations in pregnancy discusses improvement in some people during pregnancy and renewed activity afterward. Those clinical changes do not necessarily track antibody levels. Direct, lasting effects of everyday stress on anti-CCP titers are also less clearly established than the broader relationships between stress, symptoms, and immune responses.

Which other investigations can help?

Rheumatoid factor and anti-CCP provide complementary information. Some people are positive for both, others for only one, and others for neither. A figure such as 70% positive for both is not a universal estimate and should not be inferred from the sensitivity of either test alone. A review of rheumatoid factor explains its broader clinical role.

CRP and ESR can help assess inflammation, although abnormalities can have other causes. A complete blood count may reveal anemia. Complement measurements such as C3 and C4 are useful for certain autoimmune differential diagnoses but are not general measures of RA activity.

Research on HLA-DRB1 and antibodies to citrullinated proteins supports a role for genetic susceptibility. A risk-associated gene is not a diagnosis and does not, by itself, establish a need for treatment.

Vitamin D has also been studied. The initial report from the randomized VITAL trial found an approximately 22% relative reduction in confirmed new autoimmune disease over about five years with vitamin D. That was a combined autoimmune-disease outcome, not a demonstrated reduction in anti-CCP or a proven RA-prevention strategy for everyone.

The later follow-up changed the picture. After additional cases arising during the randomized phase were confirmed, the vitamin D estimate for that period was no longer statistically significant (hazard ratio 0.85; 95% confidence interval 0.70–1.04). Across seven years, including two years of post-trial observation, the estimate was 0.98 (0.83–1.17). The initial 22% figure should therefore not be presented as an established, durable protective effect. Decisions about supplementation should not be based on an anti-CCP result alone.

Frequently asked questions

Which conditions can produce a positive anti-CCP result?

The strongest association is with rheumatoid arthritis. Positive results can also occur in other inflammatory or autoimmune conditions. Often-quoted specificity estimates of 95–98% indicate that it is a useful test, not an infallible one. Performance depends on the assay and the group being tested.

What is a good CCP result?

A result classified as negative by your laboratory is generally reassuring about these antibodies. A cutoff of 20 is one example, but its units and method matter. There is no single numerical threshold for every test, and the result alone does not describe overall joint health.

What does anti-CCP below 5 mean?

It falls in the negative range of many commonly used assays. Still, check the unit and reference interval on the report. If there is joint swelling or another concerning pattern of symptoms, even a very low result does not rule out RA.

Is a rheumatoid factor of 300 high?

If the result is in IU/mL and the laboratory’s upper limit is, for example, 20 IU/mL, then 300 is substantially elevated. It should be interpreted clinically, especially with joint symptoms or positive anti-CCP. It does not prove a particular diagnosis on its own.

How stable is anti-CCP over time?

Levels often remain relatively stable. Small changes are not automatically evidence of improvement or worsening. Symptoms, the joint examination, inflammatory markers, and imaging when appropriate are more useful for assessing the course of disease and treatment response.

Can smoking play a role?

Yes. Smoking is associated with antibody-positive RA, particularly in genetically susceptible people. The benefits of quitting extend well beyond this disease and do not depend on an antibody level falling afterward.

Which additional markers are useful?

Often rheumatoid factor, CRP, and ESR, with other tests selected for the clinical situation. Genetic testing and broad autoimmune panels are not automatically necessary. The aim is to answer a clinical question rather than collect as many numbers as possible.

Is testing useful without joint symptoms?

Antibodies can appear years before symptoms, sometimes 5–10 years or longer, which is why early identification in higher-risk groups is being studied. This does not justify routine screening of every symptom-free relative. Before testing, consider what counseling and follow-up would be available if the result were positive.

Sources